What is the relationship between vaginal spotting and semaglutide (GLP1 receptor agonist)
GI symptoms, including nausea, vomiting, diarrhea, and constipation, are particularly prevalent, with incidences up to 86% in GLP-1 agonist users versus 31% in placebo groups
neurochemicals like norepinephrine play a critical role in this process
All medical, regulatory, and pricing claims were cross-referenced against publicly accessible primary sources at the time of publication (February 2026)
Tirzepatide has not been studied in patients with a prior history of pancreatitis, and it is unknown if this population is at a higher risk
Clinical perspective SGLT2is and GLP-1RAs exhibit clinical benefits on glycemic control, systolic blood pressure (SBP), body weight, and dyslipidemia, which may all partly contribute to the cardiovascular protection provided by these two drug classes [4, 19]